Effect of Systemic Retinoic Acid Use on Micro Ribonucleic Acid (mRNA) Expression

Medipol University

Status: Not yet enrolling

Conditions: Inflammation; Periodontal Diseases

Treatments: Drug: oral isotretinoin; Other: Saliva, serum sampling

Study type: Interventional

Funder types: Other

Identifiers

NCT07142070

1386

Details and patient eligibility

About

Ribonucleic acids (RNA) are molecules that transfer genetic information from the nucleus to the cytoplasm for protein translation. A subgroup of non-coding or non-messenger RNAs, known as microRNAs (miRNAs), regulates the expression of complementary mRNAs without coding for proteins. In this study, the investigators aimed to evaluate the effect of systemically administered oral isotretinoin on gingival health in terms of microRNA (miRNA), a molecule of interest in periodontal research, before, during, and after treatment.

Full description

Healthy participants (n:25) enrolled for this study. Samples will be collected for each patient at the following time points: immediately before the initiation of retinoic acid treatment, during treatment at week 5 (T1), during treatment at month 5 (T2), and three months after the end of treatment (T3).

Enrollment: 25 estimated patients

Sex: All

Ages: 18 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• systemically healthy
• over 18 and under 45 years of age
• have at least 20 natural permanent teeth in occlusion excluding third molars,
• not be pregnant,
• have not used any antimicrobial and/or anti-inflammatory drugs in the past 3 months,
• have not received periodontal treatment in the past 6 months,
• have not undergone surgical periodontal treatment within the past year.

Exclusion criteria

• history of regular use of systemic antibiotics anti-inflammatory, or antioxidant drugs (previous 3 months)
• nonsurgical periodontal treatment (previous 6 months)
• surgical periodontal treatment (previous 12 months)
• current medications affecting gingival health (calcium channel blockers, phenytoin, cyclosporine, and hormone replacement therapy)
• pregnancy

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

25 participants in 1 patient group

Experimental

Experimental group

Description:

Salivary, serum, miRNA, TNF-a observation Saliva, serum samples obtained for each patient were used for cytokine analysis. Prepared samples were analyzed for TNF-a using commercial ELISA kits (Elabscience, Houston, Texas, USA and Bioaasay Technology Laboratory (BT-Lab), Shanghai, China, respectively) according to the manufacturer's instructions.

Treatment:

Other: Saliva, serum sampling

Drug: oral isotretinoin